key: cord-0297416-1v0wt6dp
authors: Ranzani, O. T.; Leite, R. d. S.; Castilho, L. D.; Goncalves, C. C. M.; Resende, G.; de Melo, R. L.; Croda, J.
title: Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design
date: 2021-10-18
journal: nan
DOI: 10.1101/2021.10.15.21265006
sha: f8a19fef99888fdc4caa43bab67bd90effba09bd
doc_id: 297416
cord_uid: 1v0wt6dp

We used a test-negative design to estimate the vaccine effectiveness of Ad26.COV2.S (Janssen) against symptomatic COVID-19 and clinical outcomes in Mato-Grosso do Sul, Brazil. We analyzed 11,817 RT-PCR tests. The mean age was 37 (SD=17) years, 2,308 (20%) of individuals more or equal than 50 years and almost two-thirds of the population was Brown/Pardo. Adjusted effectiveness against symptomatic COVID-19 after 28 days of the single dose was 50.9% (95% CI, 35.5-63.0). Adjusted effectiveness against clinical outcomes was 72.9% (95% CI, 35.1-91.1) for hospitalization, 92.5% (95% CI, 54.9-99.6) for ICU admission, 88.7% (95% CI, 17.9-99.5) for mechanical ventilation and 90.5% (95% CI, 31.5-99.6) for death. Despite lacking precision on some estimates, a single dose of Ad26.COV2.S vaccine continues to protect specially for severe forms of COVID-19 in the context of new variants.

Ad26.COV2.S (Janssen, Johnson & Johnson) is an adenoviral vaccine against COVID-19, but unlike all other vaccine platforms, it is administered in a single dose. 1 There is limited realworld effectiveness data for Ad26.COV2.S, 2,3 and a need for more studies for this vaccine especially in the context of Gamma and Delta variants. We used a test-negative design to estimate the vaccine effectiveness of Ad26.COV2.S against symptomatic COVID19 and clinical outcomes in Mato-Grosso do Sul, a central-west state in Brazil with borders to Bolivia and Paraguay.

We analyzed data from 25-06-2021 to 30-09-2021 in Mato-Grosso do Sul state (~2.8 million inhabitants), Brazil. In Mato-Grosso do Sul, Ad26.COV2.S started to be distributed on 25-06-2021 by the national campaign program. Additionally, there was a massive campaign vaccination with Ad26.COV2.S in 13 municipalities that comprises the international borders.

During June, 2021, Mato-Grosso do Sul faced a huge COVID-19 Gamma outbreak. 4 We followed the same methodology as previously described regarding inclusion/exclusion criteria. 5, 6 Briefly, we included RT-PCR from adults residing in Mato-Grosso do Sul, collected within 10 days of symptoms onset, and excluded previous infected individuals. Our primary outcome is vaccine effectiveness after 28 days of the single dose against symptomatic COVID-19. We defined a symptomatic case as presenting at least two acute respiratory symptoms, as defined in the efficacy trial of Ad26.COV2.S. 1 Additionally, we analyzed effectiveness against hospital and ICU admissions, use of invasive mechanical ventilation and death. 6 . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint We estimated vaccine effectiveness as 1-OR from logistic regression models. We adjusted the models for age, sex, diabetes mellitus, renal, hepatic, neurologic, hematologic, cardiovascular and respiratory chronic diseases, obesity, immunosuppressed status and time (day of year). Age and day of year were modelled with a restricted cubic spline. We used the period 0-13 days after the single dose as a bias-indicator. 5 

We analyzed 11,817 RT-PCR tests. The mean age was 37±17 years, 2,308 (20%) of individuals ≥50 years and almost two-thirds of the population was Brown/Pardo. The prevalence of chronic comorbidities was low, being most frequent Diabetes mellitus (2.5%)( Table 1) .

Adjusted effectiveness against symptomatic COVID-19 after 28 days of the single dose was 50.9% (95% CI, 35.5-63.0). Adjusted effectiveness against clinical outcomes was 72.9% (95% CI, 35.1-91.1) for hospitalization, 92.5% (95% CI, 54.9-99.6) for ICU admission, 88.7% (95% CI, 17.9-99.5) for mechanical ventilation and 90.5% (95% CI, 31.5-99.6) for death. The biasindicators showed increased risk during the period 0-13 days after single dose ( Table 2) .

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

We observed an effectiveness of 51% after 28 days of a single dose of Ad26.COV2.S against symptomatic COVID-19 and higher protection against clinical outcomes. Our results should be interpreted with the following issues. We do not have sequencing of this sample, but Gamma was predominant and Delta was rapidly emerging during the study period in Brazil.

We analyzed a short follow-up period, thus we cannot evaluate potential waning on effectiveness. The bias-indicator showed residual confounding, which can be explained by the extensive outbreak that was ongoing when the vaccination started, and could indicate that our effectiveness estimates are underestimated. 5 Despite lacking precision on some estimates, a single dose of Ad26.COV2.S vaccine continues to protect specially for severe forms of COVID-19 in the context of new variants. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 18, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 18, 2021. ; https://doi.org/10.1101/2021.10.15.21265006 doi: medRxiv preprint

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Comparative Effectiveness of Moderna

Hospitalizations Among Adults Without Immunocompromising Conditions -United States

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Boletim Epidemiológico COVID-19 -Governo do Estado do Mato Grosso do Sul

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. The Lancet Regional Health -Americas

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study